作者|YY在过去短短数年间,ADC药物异军突起,重新定义了抗肿瘤治疗的价值坐标。从资本市场到制药巨头,从临床试验到并购交易,ADC成为竞相追逐的焦点。2023年,辉瑞以高达430亿美元的价格收购Seagen为“十年最大制药收购案”,不仅震动业界,更明确传递出一个信号:ADC平台不再是未来的可选项,而是当前管线升级与增长动力的核心引擎。Seagen之所以能够“朝为田舍郎,暮登天子堂”,正是因为其拥有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.